Jasper Therapeutics
JSPR
69 hedge funds and large institutions have $330M invested in Jasper Therapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 17 closing their positions.
215% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $1.03M
191% more capital inflows, than outflows
Capital inflows: $55.8M | Capital outflows: $19.2M
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
17% more funds holding
Funds holding: 59 → 69 (+10)
10.01% more ownership
Funds ownership: 86.51% → 96.52% (+10%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
+$13.9M |
| 2 |
BlackRock
New York
|
+$12M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.66M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.63M |
| 5 |
Morgan Stanley
New York
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Octagon Capital Advisors
New York
|
-$5.12M |
| 2 |
Millennium Management
New York
|
-$2.12M |
| 3 |
Ally Bridge Group
New York
|
-$1.71M |
| 4 |
Jane Street
New York
|
-$1.23M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.22M |
JSPR Hedge Fund Activity: Q2 2024 in Review
69 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2024, worth a combined $330M — down 13% from $380M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new JSPR positions and 17 closed out — a net gain of 10 holders — while 16 added to existing stakes and 11 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $13.9M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.12M.
- 69 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2024, up from 59 in Q1 2024.
- Funds reported $330M of Jasper Therapeutics stock for Q2 2024, down 13% quarter-over-quarter.
- 27 funds opened new Jasper Therapeutics positions in Q2 2024 and 17 closed out, a net change of +10 holders.
- The largest Jasper Therapeutics buyer in Q2 2024 was Polar Capital Holdings, an estimated $13.9M added.
- The largest Jasper Therapeutics seller in Q2 2024 was Octagon Capital Advisors, an estimated $5.12M sold.
Based on aggregated 13F filings for Q2 2024.